Skip to content
DataLookout
Menu

BENEFIT-HFNCT07232030

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

StatusRecruiting
PhaseNot applicable
SponsorCVRx, Inc.
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 30 versions: 28 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 23 → 26 locations
  2. Minor Study sites: 23 to 24
  3. Minor Trial sites expanded: 20 → 23 locations
  4. Minor Study sites: 21 to 22
  5. Minor Study sites: 20 to 21
  6. Minor Trial sites expanded: 14 → 20 locations
  7. Minor Study sites: 13 to 14
  8. Minor Study sites: 12 to 13
  9. Notable Eligibility criteria expanded, about 44 words
    • Study sites: 11 to 12
  10. Minor Study sites: 10 to 11v21
  11. Minor Study sites: 9 to 10v20
  12. Minor Trial status changed: Enrolling by Invitation → Recruiting
    • Site contacts updated at 3 of 9 sites
    v19
  13. Minor Trial status: Enrolling by Invitation to Recruiting
    • Study sites: 8 to 9
    v18
  14. Minor Study sites: 7 to 8v17
  15. Minor Study sites: 6 to 7v16
  16. Minor Study sites: 5 to 6v14
  17. Minor Study sites: 4 to 5v13
  18. Minor Study sites: 3 to 4
    • Start date changed from estimate of Apr 2026 to Apr 24, 2026
    v11
  19. Minor Study sites: 2 to 3v10
  20. Minor Trial status changed: Recruiting → Enrolling by Invitation
    • Site details revised at 2 of 2 sites
    v9
  21. Minor Site details revised at 1 of 2 sitesv8
  22. Minor Site contacts updated at 1 of 2 sitesv7
  23. Minor Study sites: 1 to 2v6
  24. Minor Site contact updatedv5
  25. Notable Recruitment opened
    • Start date: Mar 2026 to Apr 2026
    • Site details revised
    v4
  26. Minor Study sites: 0 to 1v3
  27. Notable Eligibility criteria shortened, about 2 words
    • Secondary endpoints: details revised at 2 of 5 entries
    v2
  28. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Primary Effectiveness Endpoint
Timeframe: Through 24-months follow-up
Primary Safety Endpoint
Timeframe: Within 180 days of the device implant

Secondary (5)

Quality of Life (QoL) Score Change
6MHW distance change
Days lost to death or hospitalization
NT-proBNP level change
All-cause mortality

Arms and interventions

Device ArmExperimental

Participants will receive Baroreflex Activation Therapy (BAT) with an implanted Barostim System in addition to usual care medical management.

Control ArmActive comparator

Participants will receive usual care medical management alone with no Barostim System device implant.

Devices: Barostim System

Other: Usual care medical management

Sites

26 sites in 1 country